We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund.

In this piece, we will look at the stocks Jim Cramer recently discussed.

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

Marking a shift from previous quarters of solid growth, the company's net profit is expected to remain flattish on year, bogged down by margin pressures due to lower Revlimid contribution and ...

Ashraf Z. Badros, MB, ChB, discusses the results of the phase 3 AURIGA trial which evaluated daratumumab and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

Revlimid is already approved to treat multiple myeloma and the blood disorder myelodysplastic syndromes. In its first quarter, Revlimid's sales totalled approximately US $1 billion.

PL Capital: The brokerage highlights that weak US base business performance will be offset by Q-o-Q growth in Revlimid sales. The integration of Sanofi's portfolio is expected to support domestic ...

Revlimid, the big-selling multiple myeloma drug acquired in Bristol’s buyout of Celgene, will face a new slate of generics in March and then a full generic market in 2026, Boerner said.